Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Management of toxic optic neuropathy via a combination of Wharton’s jelly-derived mesenchymal stem cells with electromagnetic stimulation

Fig. 3

a Visual field enlargement according to study timepoints (T0, T2) in the eye treated with combination of WJ-MSC and rEMS. Note the change in FPDI values (Table 1, patient 1: left eye). (a) Before application, FPDI 49% (b) at 4th month, FPDI 69%. b Visual field enlargement according to study timepoints (T0, T2) in the eye treated with only rEMS. Note the change in FPDI values (Table 2, patient 1: right eye). (a) Before application, FPDI 61% (b) at 4th month, FPDI 71%

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512